Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database
Objective: This study aims to explore the risk signals of osteonecrosis of the jaw induced by antiresorptive drugs and provide references for the clinical safety application.Method: According to the FDA’s Adverse Event Reporting System (FAERS), from January 2004 to September 2021, we chose “Osteonec...
Main Authors: | Jing Peng, Hui Wang, Zhen Liu, Zhen-Liang Xu, Mei-Xia Wang, Qi-Miao Chen, Ming-Li Wu, Xiao-Lei Ren, Qiu-Hua Liang, Fu-Peng Liu, Bo Ban |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1017391/full |
Similar Items
-
Knowledge and clinical behavior on antiresorptive medications and osteonecrosis of the jaws: a cross-sectional study
by: Daniel Amaral Alves MARLIÉRE, et al.
Published: (2019-12-01) -
The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review
by: Roberto Sacco, et al.
Published: (2021-01-01) -
Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents
by: Lukas Hauer, et al.
Published: (2020-03-01) -
Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis
by: Akanksha Srivastava, et al.
Published: (2021-11-01) -
Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan
by: Masanori Nashi, et al.
Published: (2023-07-01)